Clinical trial · Observational
Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion. This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALK Fusion Protein Expression | — | UNRESOLVED | — |
| ATIC-ALK Fusion Protein Expression | — | UNRESOLVED | — |
| BCR-FGFR1 Fusion Protein Expression | — | UNRESOLVED | — |
| BRAF Gene Rearrangement | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cancer Metastatic | — | UNRESOLVED | — |
| COL1A1-PDGFB Fusion Protein Expression | — | UNRESOLVED | — |
| FGFR2 Gene Translocation | — | UNRESOLVED | — |
| FGFR3 Gene Translocation | — | UNRESOLVED | — |
| Gene Fusion | — | UNRESOLVED | — |
| NTRK1 Gene Translocation |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection and quality of life questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 2 years
- description
- To describe the survival rate of patients with solid cancers harboring a NTRK fusion or other rare actionable fusion in real-life practice, according to overall survival (OS)
Secondary outcomes (13)
- measure
- Management of patient with actionable fusion
- timeFrame
- up to 48 months
- description
- Treatment scheme : number of line and type of treatments
- measure
- Time to relapse
- timeFrame
- up to 48 months
- measure
- Progression Free Survival (PFS)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with histologically-confirmed cancer * Patient harboring a rare actionable fusion (see Appendix 1), * Availability of clinical and demographic data, information on treatment and clinical outcome. * Adult, ≥18 years old, * Patient should understand, sign and date the written voluntary informed consent form. Exclusion Criteria: \-
References
Publications (0)
Data not yet available